[NMusers] NEW DDMoRe course Cardiac Safety : 18-22 Jan 2016 (extended deadline, Friday 18 Dec 2015)

From: Cheung, Amy <Amy.Cheung_at_astrazeneca.com>
Date: Mon, 14 Dec 2015 09:58:38 +0000

Model-Informed Drug Discovery and Development in Cardiac Safety

Apply here for DDMoRe Cardiac Safety
http://www.ddmore.eu/model-informed-drug-development-safety

This public Pharma lead DDMoRe course in Cardiac Safety evaluation is one i=
n a series of comprehensive face-to-face courses introducing the principles=
 of model-informed drug discovery and development, covering a range of ther=
apeutic areas, via the newly-developed DDMoRe interoperability framework.

The Department of Quantitative Clinical Pharmacology, AstraZeneca R&D Gothe=
nburg, Sweden together with the Institute of Pharmacy, Freie Universitaet B=
erlin, Germany are happy to invite you to the following face-to-face course=
:

"Model-informed Drug Development in Cardiac Safety"

Dates: 18-22 January 2016

Venue: AstraZeneca R&D Gothenburg site, Pepparedsleden 1, Mölndal, Sweden

Intended for: PhD students and Postdoctoral fellows doing research in the q=
uantitative life sciences field, but also open (if places will be available=
) to other scientists affiliated to the institutions part of the DDMoRe con=
sortium.

Topics: Model-informed drug discovery and development to evaluate cardiac s=
afety risks and with an introduction to the DDMoRe framework (new modelling=
 & simulation language, model repository, interoperability platform)

Program: Lectures, hands-on sessions, student group work, workshop, and stu=
dent presentations

Course directors: Charlotte Kloft, Zinnia Parra-Guillen, Amy Cheung, Corina=
 Dota

Fee: Free of charge (transport, accommodation and food not included)

Maximum number of participants: 20 (If needed, selection will be based on t=
he registration information, with priority to PhD students/post-docs and pa=
rticipants from different institutions).

New Application deadline: Friday, 18 December 2015

Contact: info.ddmore_at_gmail.com<mailto:info.ddmore_at_gmail.com>

For more information:
On DDMoRe and the 'education & training activities, read here:
http://www.ddmore.eu/model-informed-drug-development-safety

We warmly invite you to join us for this public Pharma lead DDMoRe course:
be among the first trained for using DDMoRe products!

________________________________

AstraZeneca UK Limited is a company incorporated in England and Wales with =
registered number: 03674842 and a registered office at 2 Kingdom Street, Lo=
ndon, W2 6BD.

Confidentiality Notice: This message is private and may contain confidentia=
l, proprietary and legally privileged information. If you have received thi=
s message in error, please notify us and remove it from your system and not=
e that you must not copy, distribute or take any action in reliance on it. =
Any unauthorised use or disclosure of the contents of this message is not p=
ermitted and may be unlawful.

Disclaimer: Email messages may be subject to delays, interception, non-deli=
very and unauthorised alterations. Therefore, information expressed in this=
 message is not given or endorsed by AstraZeneca UK Limited unless otherwis=
e notified by an authorised representative independent of this message. No =
contractual relationship is created by this message by any person unless sp=
ecifically indicated by agreement in writing other than email.

Monitoring: AstraZeneca UK Limited may monitor email traffic data and conte=
nt for the purposes of the prevention and detection of crime, ensuring the =
security of our computer systems and checking compliance with our Code of C=
onduct and policies.

Received on Mon Dec 14 2015 - 04:58:38 EST

This archive was generated by hypermail 2.3.0 : Fri Sep 27 2019 - 16:47:59 EDT